Activating FLT3 mutations are detectable in chronic and blast phases of chronic myeloproliferative disorders other than chronic myeloid leukemia

American Journal of Clinical Pathology

Volumn 126, Issue 4, 2006, Pages 530-533

  Lin, Pei ^a   Jones, Dan ^a   Medeiros, L Jeffrey ^a   Chen, Weina ^a   Vega Vazquez, Francisco ^a   Luthra, Rajyalakshmi ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myeloproliferative disorders; FLT3 gene mutations

Indexed keywords

FLT3 LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; GENE DUPLICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; INTERNAL TANDEM DUPLICATION; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION RATE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; PRIORITY JOURNAL;

EID: 33749364564     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/JT5BE2L1FGG8P8Y6     Document Type: Article

References (20)

1. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat RED Cancer. 2003;3:650-665.
2. Kottaridis PD, Gale RE, Linch DC. Flt3 mutations and leukaemia. Br J Haematol. 2003;122:523-538.
3. Lee BH, Williams IR, Anastasiadou E, et al. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene. 2005;24:7882-7892.
4. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-4335.
5. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59-66.
6. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia. 1997;11:1605-1609.
7. Horiike S, Yokota S, Nakao M, et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia. 1997;11:1442-1446.
8. Taketani T, Taki T, Sugita K, et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood. 2004;103:1085-1088.
9. Paietta E, Ferrando AA, Neuberg D, et al. Activating FLT3 mutations in CD117/KIT+ T-cell acute lymphoblastic leukemias. Blood. 2004;104:558-560.
10. Pardanani A, Reeder TL, Kimlinger TK, et al. Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res. 2003;27:739-742.
11. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature. 2005;434:1144-1148.
12. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
13. Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
14. Kiyoi H, Naoe T. FLT3 in human hematologic malignancies. Leuk Lymphoma. 2002;43:1541-1547.
15. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434-2439.
16. Chen W, Jones D, Medeiros LJ, et al. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. Br J Haematol. 2005;130:726-727.
17. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
18. Hao S, Sanger W, Onciu M, et al. Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod Pathol. 2002;15:12664272.
19. Suzuki M, Abe A, Kiyoi H, et al. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation [letter]. Leukemia. 2006;20:1168-1169.
20. Spiekermann K, Dirschinger RJ, Schwab R, et al. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood. 2003;101:1494-1504.